3-hydroxy-5-tert-butylisoxazole | 107403-12-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-hydroxy-5-tert-butylisoxazole
• 英文别名: 5-t-butyl-3-hydroxyisoxazole；5-tert-butyl-1,2-oxazol-3-one
• CAS: 107403-12-3
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: NZLCEIYRRDWTEV-UHFFFAOYSA-N

物化性质

• 熔点：
  101-102 °C
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  3-hydroxy-5-tert-butylisoxazole 在 氢溴酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 4-bromomethyl-2-methoxymethyl-5-tert-butylisoxazolin-3-one
  参考文献：
  名称：

  Excitatory amino-acid receptor agonists. Synthesis and pharmacology of analogues of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid

  摘要：

  We have previously proposed the existence of a lipophilic cavity of the 2-amino-3-(3-hydroxy-5-methylisoxazol4-yl)propionic acid (AMPA) receptor recognition site capable of accommodating alkyl substituents of limited size in the 5-position of the isoxazole ring. In order to indirectly elucidate the approximate extent of this proposed cavity we have synthesized and pharmacologically characterized a number of AMPA analogues. For most of these AMPA analogues, a positive correlation between AMPA receptor affinity and agonist effect was observed. The only exception was demethyl-AMPA (8a), which showed relatively high AMPA receptor affinity (IC50 = 0.27 mu M) but remarkably weak agonist potency (EC50 = 900 mu M). Whereas the ethyl analogue of AMPA (Et-AMPA) (IC50 = 0.030 mu M; EC50 = 2.3 mu M) has previously been shown to be slightly more potent than AMPA (IC50 = 0.040 mu M; EC50 = 3.5 mu M), substitutions of a propyl or a butyl group for the methyl group of AMPA to give 8b (IC50 = 0.090 mu M; EC50 = 5.0 mu M) or 8f (IC50 = 1.0 mu M; EC50 = 32 mu M), respectively, result in progressive loss of the AMPA agonist effect. Analogues containing larger groups, such as isopentyl (8e), 1-propylbutyl (8g), 2,2-dimethylpropyl (8h), or benzyl (14) groups, were very weak or totally inactive as AMPA receptor ligands.

  DOI：

  10.1016/s0223-5234(97)89085-x
• 作为产物：
  描述：

  特戊酰基乙酸乙酯 在 sodium hydroxide 、 盐酸羟胺 作用下， 反应 2.0h， 生成 3-hydroxy-5-tert-butylisoxazole
  参考文献：
  名称：

  神经兴奋剂2-氨基-3-（3-羟基-5-叔丁基异恶唑-4-基）丙酸（ATPA）的两种对映体的对映选择性合成

  摘要：

  的两种对映体的制备2-氨基-3-（3-羟基-5-叔丁基异恶唑-4-基）丙酸（ATPA），1，所述neuroexcitant 2-氨基-3-（3-羟基的类似物描述了（-5-甲基-4-基）丙酸（AMPA）。对映体纯的甘氨酸衍生物叔丁氧基羰基-2-（叔丁基）-3-甲基-4-氧代-1-咪唑烷羧酸酯（BOC-BMI）与4-溴甲基-2-甲氧基甲基-5-叔丁基异唑啉- 3-一6给出中间体（2 R，5 R）-8和（2 S，5 S）-8。这些烷基化产物在温和条件下水解，得到对映纯（R）-1和（S）-1，ee超过99％，总收率33％。

  DOI：

  10.1016/s0957-4166(00)00484-5

文献信息

• NEPRILYSIN INHIBITORS
  申请人：Fleury Melissa

  公开号：US20150210690A1

  公开（公告）日：2015-07-30

  In one aspect, the invention relates to compounds having the formula I: where R 1 -R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下式I的化合物： 其中R1-R6如规范中定义，或其药学上可接受的盐。这些化合物具有神经肽酶抑制活性。在另一个方面，该发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• CYSTOBACTAMIDES
  申请人：HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH

  公开号：US20160145304A1

  公开（公告）日：2016-05-26

  The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections:

  本发明提供了式（I）的囊胞菌素及其用于治疗或预防细菌感染的用途：
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Ren Pingda

  公开号：US20120122838A1

  公开（公告）日：2012-05-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法在此进行描述。
• PPAR active compounds
  申请人：Lin Jack

  公开号：US20080249137A1

  公开（公告）日：2008-10-09

  Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.

  描述了对至少PPARα、PPARδ和PPARγ中的一个活性的化合物，这些化合物对涉及至少PPARα、PPARδ和PPARγ中的一个的治疗和/或预防方法是有用的。
• Arginase Inhibitors and Their Therapeutic Applications
  申请人：OncoArendi Therapeutics S.A.

  公开号：US20170319536A1

  公开（公告）日：2017-11-09

  Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.

  揭示了一种小分子治疗化合物，它们是较强的精氨酸酶1和精氨酸酶2活性抑制剂。还揭示了包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与精氨酸酶活性相关的疾病或状况的方法。